A recent report outlines three investigational hair loss treatments. Review the science, clinical trial data, and limitations of these emerging candidates.
On September 24, 2026, Dermatology Times reported on three investigational therapies advancing through clinical trials for androgenetic alopecia. The coverage highlighted topical clascoterone, an extended-release oral minoxidil formulation called VDPHL01, and a topical candidate known as PP405. These potential treatments aim to address the biological mechanisms behind common hair thinning. While they remain experimental and unapproved, they represent a broadening pipeline of scientific research. Health-conscious adults often track these developments to understand where clinical options might be heading next.
The recent coverage focuses specifically on androgenetic alopecia, frequently abbreviated as AGA. This condition involves gradual follicular miniaturization, leading to thinner and shorter hair cycles over time. The sources distinguish AGA from alopecia areata, which is an entirely different form of hair loss driven by distinct immune responses. The three candidates mentioned in the pipeline report take unique approaches to maintaining a healthy follicle environment over the long term.
Clascoterone is designed to work locally as an androgen-receptor inhibitor. By acting directly on the scalp, it aims to block the specific hormonal signals that cause follicles to shrink in patients with AGA. In contrast, PP405 is intended to reactivate follicular stem cells to encourage new growth cycles. The third candidate, VDPHL01, offers an extended-release version of an established medication, aiming to provide a steadier systemic effect.
The distinctions between these treatments matter because hair follicles are complex biological structures. They rely on a precise balance of hormones, blood flow, and cellular signals to maintain their natural growth phases. When androgenetic alopecia disrupts this environment, the active growth phase shortens while the resting phase extends. By targeting either the hormonal triggers or the stem cells responsible for regeneration, these pipeline candidates represent a highly specific approach to follicular biology.
Dermatology Times shared specific trial metrics to illustrate how these candidates are performing, though these findings come from highly controlled environments. For topical clascoterone, the phase 3 SCALP-1 and SCALP-2 trials enrolled 1,465 men across 51 testing sites in the United States and Europe. The resulting data showed a relative target-area hair count improvement versus a vehicle solution of 539% in SCALP-1 and 168% in SCALP-2. Investigators reported a safety profile comparable to the vehicle through 12 months, noting no signal of systemic hormonal effects during that period.
The extended-release oral minoxidil candidate, VDPHL01, recently completed a 519-patient trial in men. At the six-month mark, participants experienced mean increases in non-vellus hair count of 30.3 hairs per square centimeter with once-daily dosing. Twice-daily dosing yielded slightly higher results at 33.0 hairs per square centimeter, compared with just 7.3 for the placebo group. The cited report indicates that the trial met all primary and secondary endpoints, and adverse event rates were similar to those seen in the placebo group.
The early-stage data for the stem-cell reactivator, PP405, comes from a smaller phase 2a trial of 78 men and women. In a specific subgroup of men with more advanced hair loss, 31% saw a hair density increase greater than 20% at week eight. By comparison, the placebo group saw a 0% response rate in that same eight-week timeframe. The report noted that phase 3 trials for this candidate were planned for 2026.
It is important to remember that these trials measured specific types of hair growth under clinical supervision. Non-vellus hairs are the thicker, pigmented strands that contribute to visible hair volume, rather than the fine, lightly colored hairs found elsewhere on the body. By measuring these specific strands, researchers attempt to quantify genuine cosmetic improvements rather than just microscopic changes. These rigorous measurement standards help clinicians compare new data against historical benchmarks in hair science.
While these numbers appear significant, reading clinical news requires recognizing clear scientific limitations. None of these three candidates is currently approved or proven effective for routine clinical use. The cited coverage presents controlled trial data, not a guarantee that these formulas will become available treatments. Promising pipeline data is not a substitute for established medical consensus.
The reported trials are also at vastly different stages of maturity. Clascoterone has formal phase 3 data, VDPHL01 has a six-month trial result, and PP405 only has early phase 2a subgroup findings. Treating these candidates as having equivalent levels of evidence would misrepresent the scientific reality. Furthermore, much of the most impressive data was measured exclusively in male populations or in very narrow subgroups.
A mean hair count increase does not reflect the exact result every single user will experience in the real world. The impressive clascoterone percentages represent relative improvements versus an inactive vehicle, not a direct comparison to other active treatments. Similarly, safety profiles labeled comparable to a vehicle do not prove a treatment is entirely free of side effects for every individual. Long-term safety beyond the observed trial periods remains unknown, meaning these investigational treatments still have hurdles to clear.
The reporting surrounding these trials also highlights a common issue in medical news interpretation. Dermatology Times frames these developments as notable pipeline news relevant to future clinician discussions, not as immediate consumer recommendations. A promising trial result simply means a candidate warrants further study, not that it is ready for public distribution. Assuming that an experimental formula is superior to standard care based on early trial numbers often leads to unrealistic expectations.
Health-conscious women looking to support their hair density should view this pipeline news as educational background rather than immediate guidance. If you are noticing changes in your hair volume, the first practical step is securing an accurate diagnosis from a qualified professional. Since these new developments specifically target androgenetic alopecia, you need to know if your thinning stems from AGA or another entirely different cause. Discussing your specific situation with a dermatologist ensures you target the correct biological mechanism.
When evaluating new claims in the beauty industry, it is crucial to distinguish between reported trial data and available care. Media headlines often frame early-phase research as established fact. Checking the condition studied, the trial phase, and the demographics involved will help you evaluate what the numbers actually mean. Learning to read these nuances empowers you to make better choices when evaluating how hair changes over time.
Build your daily regimen around established clinical realities rather than waiting for experimental candidates to hit the market. Maintaining overall scalp health, addressing your body's nutrition for healthy aging, and protecting existing strands from physical damage remain foundational steps. Just as you might adapt to environmental factors affecting your skin, adjusting your hair care based on proven methods yields the best long-term results. A consistent and evidence-based approach will consistently outperform the pursuit of unverified trends.
The steady progress of candidates like clascoterone and VDPHL01 highlights a major shift toward targeted cellular interventions. Researchers are moving past generalized solutions to address the precise hormonal and stem-cell mechanisms involved in follicular decline. As these late-stage clinical trials mature and new data emerges, the focus will turn to broad applicability and long-term safety. Will the next decade of beauty science finally transition daily hair care from superficial maintenance to precise, biologically targeted support?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
